Fig. 2From: Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factorsReceiver operating characteristic curve analysis of the optimal cut-off for the time from ADT to castration resistanceBack to article page